Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation
NCT02945033Phase 3Active, not recruiting
- Sponsor
- Rouen University Hospital
- Start
- Jul 2018
- Primary completion
- Jul 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in colorectal cancer (CRC) comparing Aspirin with Placebo (2 arms). Primary endpoint: Disease-Free Survival at 3 years. Started Jul 2018; status: active, not recruiting.
02
Drugs
aspirin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02945033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02945033.